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PennsylvaniaABSTRACT The tyrosine phosphorylated epidermal growth factor receptor (EGFR) initiates numerous cell signaling
pathways. Although EGFR phosphorylation levels are ultimately determined by the balance of receptor kinase and protein
tyrosine phosphatase (PTP) activities, the kinetics of EGFR dephosphorylation are not well understood. Previous models of
EGFR signaling have generally neglected PTP activity or computed PTP activity by considering data that do not fully reveal
the kinetics and compartmentalization of EGFR dephosphorylation. We developed a compartmentalized, mechanistic model
to elucidate the kinetics of EGFR dephosphorylation and the coupling of this process to phosphorylation-dependent EGFR
endocytosis. Model regression against data from HeLa cells for EGFR phosphorylation response to EGFR activation, PTP inhi-
bition, and EGFR kinase inhibition led to the conclusion that EGFR dephosphorylation occurs at the plasma membrane and
in the cell interior with a timescale that is smaller than that for ligand-mediated EGFR endocytosis. The model further predicted
that sufficiently rapid dephosphorylation of EGFR at the plasma membrane could potentially impede EGFR endocytosis, consis-
tent with recent experimental findings. Overall, our results suggest that PTPs regulate multiple receptor-level phenomena via
their action at the plasma membrane and cell interior and point to new possibilities for targeting PTPs for modulation of
EGFR dynamics.INTRODUCTIONThe binding of SH2- and PTB-domain-containing proteins
to phosphorylated C-terminal tyrosines of the epidermal
growth factor receptor (EGFR) links the receptor to cell-
signaling pathways and to receptor trafficking mechanisms
(1). Whereas the processes leading to EGFR tyrosine
phosphorylation have been studied in detail, relatively little
is known about quantitative aspects of receptor dephosphor-
ylation by protein tyrosine phosphatases (PTPs) (2,3). Esti-
mates of the rates of EGFR tyrosine dephosphorylation are
limited (4–6), and the extent to which individual PTPs
contribute to the net dephosphorylation kinetics of specific
EGFR phosphotyrosines is unknown. The relative rates of
EGFR tyrosine dephosphorylation at different cellular loca-
tions also remain poorly understood.
Beyond this fundamental knowledge gap, there are
additional reasons why a quantitative understanding of
EGFR tyrosine dephosphorylation is important. Indeed,
dephosphorylation rates may influence receptor inhibition
by targeted therapeutics (3), receptor trafficking (7), and
downstream signaling (8). Tyrosine cycling between phos-
phorylated and unphosphorylated forms may also influ-
ence receptor sensitivity to noise (9), system responses
to changes in ligand concentration (10), and sensitivity to
changes in PTP and receptor concentrations (11). Of course,
phosphatases play important roles in regulating signaling
downstream of the receptor as well. In linear signaling
cascades such as those associated with MAP kinases, phos-Submitted June 1, 2011, and accepted for publication March 14, 2012.
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amplification, and dampening (12).
A number of PTPs that regulate EGFR have been identi-
fied, including RPTPs, RPTPk, LAR, SHP-1, PTP1B,
TCPTP, CDC25A, DEP-1, and LRP, with some information
available on PTP localization. RPTPs, RPTPk, LAR,
DEP-1, and LRP are anchored to the plasma membrane
(13), whereas SHP-1 is present throughout the cytoplasm
(14). PTP1B is tethered to the cytoplasmic side of the endo-
plasmic reticulum (15) and may be released into the cyto-
plasm (16), whereas TCPTP (16) and CDC25A (17) are
shuttled between the nucleus and cytoplasm. Such spatial
organization leads to important consequences for the
dynamics of EGFR phosphotyrosine regulation by specific
PTPs. For example, PTP1B dephosphorylates EGFR mainly
after receptor endocytosis (18). In contrast, DEP-1’s locali-
zation to the plasma membrane allows it to dephosphorylate
EGFR before endocytosis in a process that may affect EGFR
internalization (7).
The incomplete understanding of EGFR tyrosine dephos-
phorylation is reflected by the different ways this process
has been incorporated into computational models of
EGFR dynamics. One recent model simply assumed iden-
tical EGFR dephosphorylation rate constants for the plasma
membrane and cell interior (5), while another included PTP
effects without incorporating receptor trafficking (4). In
previous models assuming that EGFR internalization is
driven by ligand occupancy, neither phosphorylated species
nor receptor dephosphorylation were explicitly included
(19,20). In previous models of EGFR-mediated sig-
naling focused on effects of receptor internalization ondoi: 10.1016/j.bpj.2012.03.037
FIGURE 1 Model topology. (A) Binding processes include EGFR inter-
actions with itself, EGF, ATP, and an EGFR kinase inhibitor (INH). (B)
Additional processes include phosphorylation, dephosphorylation, and
receptor trafficking.
EGFR Regulation by Phosphatases 2013downstream signaling (21) and network branching (22),
dephosphorylation was omitted, presumably due to a focus
on downstream dynamics. Another recent computational
study concluded that ErbB receptors are mainly dephos-
phorylated in the cell interior (6). However, that model
did not include explicit phosphorylation or dephosphoryla-
tion reactions; equated dimers with phosphorylated recep-
tors; and assumed that dephosphorylation was equivalent
to dimer uncoupling.
Here, we develop a mechanistic model to gain quantita-
tive insight into the process of EGFR tyrosine dephosphor-
ylation and its impact on other EGFR rate processes. The
model consists of a set of coupled ordinary differential
equations that describe the kinetics of EGFR phosphoryla-
tion, dephosphorylation, and trafficking. The model con-
siders the dynamics of a single representative cytoplasmic
EGFR tyrosine and accounts for the well-established
coupling between receptor phosphorylation and endocytosis
by requiring that receptors be phosphorylated for endocy-
tosis to occur. Most parameters were taken from the litera-
ture or estimated using established methods. An additional
aspect of our approach is fitting the four unknown parame-
ters (including rate constants for EGFR tyrosine dephos-
phorylation at the plasma membrane and in the cell
interior) to data gathered in HeLa cells for EGFR Y1068
phosphorylation response to EGFR activation by EGF,
EGFR kinase inhibition, and PTP inhibition. These
dynamic responses were quantified as percentages of phos-
phorylated EGFR using an immunoprecipitation-based
method. Overall, our model results suggest that EGFR
dephosphorylation occurs rapidly at the plasma membrane
and in the cell interior in HeLa cells with a timescale that
is smaller than that for EGF-mediated EGFR endocytosis.
These dephosphorylation kinetics are predicted to exert
control over EGFR endocytosis, EGFR inhibition, and
phosphorylation sensitivity to changes in EGFR expression
levels.MATERIALS AND METHODS
Model development
General model considerations and topology
The model consists of a set of coupled ordinary differential equations that
describe interactions of EGFR with itself (dimerization and phosphoryla-
tion), PTPs, EGF, ATP, and the EGFR kinase inhibitor gefitinib (Fig. 1 A).
As these processes occur, EGFR is routed from the plasma membrane to
an endosomal compartment where it is sorted for recycling or degradation
(Fig. 1 B). Essential processes and model parameters are summarized in
Fig. 1 and Table 1, respectively. The model includes 169 reactions, 52
species, and 25 parameters.
EGF binding, trafficking, and concentration
EGF binding at the plasma membrane and in the endosome was modeled as
a reversible process characterized by rate constants for binding at pHs char-
acteristic of these locations (23). EGF concentration was assumed to beconstant in the extracellular space and time-dependent in the endosomal
compartment.
ATP and inhibitor binding
Rate constants for ATP and gefitinib association with EGFR were estimated
assuming diffusional limitations. Gefitinib was assumed to have a diffusivity
of 2.5  106 cm2$s1, equal to that of ATP (24), and an interaction radius
of 1 nm with EGFR (25). The rate constant for gefitinib dissociation was
computed using its affinity for the EGFR kinase (26). The rate constant
for ATP dissociation was estimated using an equilibrium-binding model
and assuming that, for an ATP concentration of 1 mM (27), half of
EGFR is inhibitor-bound at 21 nM gefitinib, consistent with experimental
measurements (28).
EGFR dimerization
Rate constants for receptor dimerization were estimated assuming diffu-
sional limitations (25), as in previous models (4,20). The diffusivity of
EGFR was set to 1  1010 cm2$s1 (4), and the interaction radius was
set to 1 nm (25). Cells and endosomes were approximated as spheres of
radii 10 mm and 350 nm (29), respectively. Dimerization constant estimates
were sensitive to changes in area but not to changes in EGFR levels.
Thus, distinct dimerization rate constants were computed for the plasma
membrane and endosome assuming 5  104 EGFR per compartment.
Because EGF binding to EGFR promotes dimer formation (30), we defined
dimer uncoupling rate constants for ligand-bound (kdE,r) and ligand-free
(kd,r) EGFR, as in previous models (20,22). These constants were included
in the parameter fit.
EGFR phosphorylation
EGFR phosphorylation was modeled as a process occurring within ATP-
bound EGFR dimers during which both receptors are phosphorylated at
a representative tyrosine. These reactions were characterized by rate
constants for EGFR catalytic activity in the presence or absence of EGF
(31). This structure allows for a small amount of EGFR phosphorylation
in the absence of ligand, which has been observed even in the presence
of a ligand-blocking antibody (32). The simplification of modeling EGFR
phosphorylation at a single tyrosine residue has been used in previous
EGFR models (e.g., (4,21)). Provided that the tyrosine considered plays
a critical role in receptor endocytosis, this simplification should be accept-
able for our purposes. Because the dynamics with which different EGFRBiophysical Journal 102(9) 2012–2021
FIGURE 2 Relationship between model (ke,m) and experimental (ke,e)
rate constants for EGFR endocytosis. The relationship between ke,m and
ke,e was determined for 10 ng/mL EGF and (A) kdp,s ¼ 1.7, 17, or
170 min1 and (B) EGFR expression of 5 103, 5 104, or 5 105 cell1.
For a given ke,m, the SE was computed and ke,e was calculated.
TABLE 1 Model parameters
Parameter Description Value Source
kE,fs (mM
1$min1) EGF binding to EGFR, forward, surface 6.3  101 (23)
kE,rs (min
1) EGF binding to EGFR, reverse, surface 1.6  101 (23)
kE,fi (endosome$min
1) EGF binding to EGFR, forward, interior 3.9  104 (23)
kE,ri (min
1) EGF binding to EGFR, reverse, interior 6.6  101 (23)
kA,f (mM
1$min1) ATP binding to EGFR, forward 1.0  105 See text
kA,r (min
1) ATP binding to EGFR, reverse 1.1  107 See text
ki,f (mM
1$min1) Inhibitor binding to EGFR, forward 1.0  105 See text
ki,r (min
1) Inhibitor binding to EGFR, reverse 2.1  102 See text
kd,fs (cell$min
1) EGFR dimerization, forward, surface 6.7  104 See text
kd,fi (endosome$min
1) EGFR dimerization, forward, interior 1.1  102 See text
kd,r (min
1) EGFR dimerization, reverse, unoccupied 1.2  104 Fit
kdE,r (min
1) EGFR dimerization, reverse, EGF-occupied 1.0  1010 Fit
kcat (min
1) Phosphorylation, unoccupied dimer 2.7  100 (31)
kcatE (min
1) Phosphorylation, EGF-occupied dimer 1.3  101 (31)
kdp,s (min
1) Dephosphorylation, surface 1.7  100 Fit
kdp,i (min
1) Dephosphorylation, interior 1.5  100 Fit
SE (cell
1$min1) EGFR synthesis Varies See text
ke,m (min
1) Phosphorylated EGFR internalization Varies See text
kexE (min
1) Endosomal exit, EGF-occupied 4.0  102 (19)
kex (min
1) Endosomal exit, unoccupied 4.0  102 (19)
frE Recycle fraction, EGF-occupied 0.5 (19)
fr Recycle fraction, unoccupied 0.8 (19)
ATP (mM) Cellular ATP concentration 1.0  103 (27)
EGF (mM) Extracellular EGF concentration Varies See text
INH (mM) Inhibitor concentration Varies See text
2014 Monast et al.tyrosines become phosphorylated (33) and dephosphorylated (28) appear to
be roughly equivalent, the kinetics of tyrosine phosphorylation suggested
by our model are likely representative of most EGFR tyrosines.
PTP activity
EGFR dephosphorylation was modeled as zeroth order with respect to PTPs,
which obviates the need to specify PTP concentrations. To accommodate
the possibility of different dephosphorylation rates at the plasma membrane
and in the cell interior, we defined distinct parameters for these locations
(kdp,s and kdp,i, respectively), which were included in the parameter fit.
EGFR endocytosis and synthesis
Movement of phosphorylated EGFR from the plasma membrane to the cell
interior (endocytosis) was modeled as a first-order process with a rate
constant ke,m. The specific endocytosis rate constant ke,e has been measured
using 125I-EGF, with ke,e computed as the slope of internalized
125I-EGF
counts versus the integral of surface-bound 125I-EGF counts from t ¼ 0
to the time of the measurement, for a series of times (34). A ke,e computed
in this way is not generally interchangeable with the ke,m used in model rate
equations describing endocytosis of phosphorylated species, even though
the constants have similar units. This inconsistency arises because PTP
activity at the plasma membrane results in at least some of the ligand-
bound, membrane-localized receptors being unphosphorylated. In the limit
of vanishing PTP activity at the membrane and rapid dimerization and phos-
phorylation, ke,m / ke,e. To ensure that our results accurately reflected
experimentally determined ke,e values, ke,m was iteratively determined for
each simulation to achieve agreement between predicted internal and
plasma membrane EGF dynamics and a ke,e ¼ 0.13 min1 (35).
For our best-fit parameters (Table 1), ke,m was ~1.6-fold larger than ke,e.
Based on the discussion above, it is not surprising that the difference
depends upon kdp,s (Fig. 2 A), with larger kdp,s values increasing the
discrepancy between ke,e and ke,m. The difference also depends upon
EGFR expression because increased expression promotes dimerization
and phosphorylation (Fig. 2 B). In Fig. 2, A and B, ke,e plateaus for arbi-
trarily large ke,m values as other processes become rate-limiting.Biophysical Journal 102(9) 2012–2021Because our model accounts for a small rate of EGFR degradation even
in the absence of EGF, we incorporated an EGFR synthesis rate SE to allow
for steady initial EGFR levels. The SE and ke,m values were determined iter-
atively before model calculations.
Endosomal exit and sorting
Receptor exit from the endosome was modeled using previously published
parameters (19). The sorting of exiting species for degradation and recy-
cling was modeled by assuming that constant fractions were routed to these
pathways (19). EGFR sorting fractions were taken from measurements in
mammary epithelial cells (19).
Parameter fitting
To determine the four unknown parameters, we began by fitting the model
to data gathered from parental HeLa cells, including the phosphorylation
FIGURE 3 Model recapitulation of experimental EGFR phosphoryla-
tion measurements. The percentage of EGFR phosphorylated at Y1068
(%pEGFR) was measured for several experimental conditions using the
approaches outlined in the Supporting Material. Data are represented as
averages5 SE and were fit to determine four parameters, as described in
the Materials and Methods. Measurements and model calculations were
made for: (A) 1 or 10 ng/mL EGF treatment of parental HeLa cells; (B)
100 mM pervanadate (PV) treatment of parental HeLa cells (simulated by
setting kdp,s ¼ kdp,i ¼ 0 min1); (C) 8 min treatment with 1 or 10 ng/mL
EGF followed by 4 mM gefitinib (pulse-chase; PC) of parental HeLa cells;
and (D) pulse-chase conditions as in panel C in HeLa.DynK44A cells (ke,e ¼
0.01 min1 (35)). Note that, in panels C and D, t¼ 0 min corresponds to the
EGFR Regulation by Phosphatases 2015response of EGFR Y1068 to 1 and 10 ng/mL EGF, 100 mM pervanadate,
and EGF-gefitinib pulse-chase (see Fig. S1). To refine our fits, we also
included pulse-chase data from HeLa cells with conditional expression of
dominant negative dynamin (HeLa.DynK44A), which inhibits EGFR endo-
cytosis (see Fig. S1). Measurements in cells with conditional expression
of wild-type dynamin (HeLa.DynWT) matched data from parental HeLa
cells and were not included to avoid biasing the regression. Time-courses
were restricted to t % 20 min to minimize potential effects of transcrip-
tional regulation. Because our preliminary analysis revealed that data for
the fraction of receptor phosphorylated would constrain parameter esti-
mates more than data for relative changes in phosphorylation alone, we con-
verted our immunoblot data to estimates of the percentage of EGFR
phosphorylated at Y1068 (%pEGFR) using immunoprecipitation-based
measurements (see Fig. S2), as described in the Supporting Material.
Parameter fitting was accomplished using simulated annealing to mini-
mize the total error between model predictions and experimental data.
For most data points, errors were computed as the square of the difference
between model prediction and the experimental value divided by the magni-
tude of the experimental value. For pulse-chase data points, a similar form
was used, except that experimental and model values were normalized to
their values at 8 min post-EGF. This emphasized the fold-changes in
pEGFR signals observed in the pulse-chase experiments. The error associ-
ated with each treatment (e.g., 1 ng/mL EGF) was computed as the sum of
individual data point errors divided by the number of points for that condi-
tion, and the total error was computed as the sum of these treatment condi-
tion errors. The best-fit results are included in Table 1.
Sensitivity analysis
Model sensitivity to changes in parameters was computed by increasing and
decreasing the values in Table 1 by factors of 2, 10, and 100. To compute
raw measures of sensitivity, we summed the integrated differences between
the base model and the two perturbed outputs over time. To compare
different perturbation magnitudes, raw sensitivities for a given perturbation
were reported as percentages of the maximum.
Model scope
To aid computational efficiency, our model topology assumed all dimer
species to be symmetric (e.g., EGF binds both or neither EGFR monomers
in a dimer). To test whether this simplification significantly affected
our conclusions, we expanded the model to allow for asymmetric ligand
binding. This increased the number of species from 52 to 119 and the
number of reactions from 169 to 499, without changing the number of
parameters. We refit the unknown parameters and found that kdp,s and
kdp,i were nearly identical to the values found in the first fit (see Table S1
in the Supporting Material), although the dimer uncoupling constants
changed to accommodate the increased number of species. All remaining
calculations were based on the more compact model.
Representative HeLa cell
Unless otherwise noted, calculations reflect 5  104 EGFR/cell (36) and
ke,e ¼ 0.13 min1 (35). For HeLa.DynK44A cells, calculations reflect
ke,e ¼ 0.01 min1 (35).
Model implementation
Codes were generated and compiled using the Systems Biology Toolbox 2
(SBT2) package for MATLAB (37) (The MathWorks, Natick, MA). The
simulannealbnd function in the Global Optimization Toolbox was used to
fit the model to experimental data.time when the gefitinib chase was added to cells. (Dashed lines) Model
results generated using parameters from a fit to parental HeLa data only
(A–C); (solid lines) model results generated using parameters from a fit
to all data (A–D). Model and experimental results for 1 ng/mL EGF
(gray lines/open circles); 10 ng/mL EGF (black lines/solid circles); and
PV (black lines/open diamonds).Experimental methods
Using a combination of immunoprecipitation and immunoblotting, we
generated quantitative estimates of %pEGFR in HeLa cells in response totreatment with EGF, pervanadate, or gefitinib for t % 20 min. These data
were used to fit model parameters, as described above. Complete details
on the experimental methods can be found in the Supporting Material.RESULTS
EGFR phosphorylation dynamics in HeLa cells
Experimental measurements of %pEGFR for 20 min treat-
ment with 1 ng/mL EGF, 4 min treatment with 10 ng/mL
EGF, and 20 min treatment with 100 mM pervanadate
were 11.65 0.7%, 35.75 6.8%, and 13.15 2.7%, respec-
tively. As described in the Supporting Material, these
measurements were used to convert immunoblot data to
estimates of %pEGFR for all time points (Fig. 3).
Treatment of parental HeLa cells with EGF or pervana-
date resulted in time-dependent induction of EGFR Y1068Biophysical Journal 102(9) 2012–2021
2016 Monast et al.phosphorylation (Fig. 3,A andB, and Fig. S1), with estimated
%pEGFR values as high as ~45% for a 20-min treatment
with 10 ng/mL EGF. In response to pervanadate, %pEGFR
levels rose as high as ~15%, an effect that is qualitatively
consistent with previous results (e.g., Offterdinger et al.
(38)). When parental cells were treated for 8 min with 1 or
10 ng/mL EGF and then treated with 4 mM gefitinib, pEGFR
levels returned to baseline levels within ~1min after gefitinib
addition (Fig. 3 C and see Fig. S1). Similar trends in EGFR
phosphorylation dynamics for such pulse-chase experiments
have been previously reported (e.g., Offterdinger et al. (38)).
To directly probe EGFR dephosphorylation at the plasma
membrane, pulse-chase experiments were also performed
in HeLa.DynK44A cells. Even with impaired EGFR endocy-
tosis, EGFR was dephosphorylated within ~1 min after
gefitinib addition (Fig. 3 D and see Fig. S1).FIGURE 4 Effect of variation in surface (kdp,s) and interior (kdp,i)
dephosphorylation rate constants on model agreement with EGFR phos-
phorylation measurements. Model error was calculated for ranges of kdp,s
and kdp,i considering: (A) all data from parental HeLa cells, (B) all data
from parental and HeLa.DynK44A cells, (C) EGF treatment in parental
HeLa cells only, (D) EGF-gefitinib pulse-chase experiments in par-
ental HeLa cells only, (E) EGF-gefitinib pulse-chase experiments in
HeLa.DynK44A cells only, and (F) pervanadate treatment in parental
HeLa cells only. For these calculations, kdp,s and kdp,i were set before
computing ke,e and SE. (Red circles) Error minima. To compare different
plots on an equal basis, the scale was defined as the log of the error divided
by the log of the global error minimum.Model fitting to experimental data
Parameter fitting revealed that data from parental HeLa cells
only were best recapitulated when kdp,i and kdp,s were of
similar magnitudes, with kdp,i > kdp,s (see Table S2, entry
for K44A PC removed). Even though kdp,i was larger than
kdp,s, the magnitude of kdp,s suggests significant regulation
of EGFR by PTPs at the plasma membrane. The fit results
also suggest a difference in kdE,r and kd,r which is larger
than previously reported (20,22), which is a consequence
of topological differences between our model and previous
models. Using these fitted parameters, the model recapitu-
lated the EGFR phosphorylation data in parental cells re-
asonably well (Fig. 3, A–C, dashed lines). Response to
pervanadate was well captured by the model, and, with the
exception of the response to 10 ng/mL EGF at 4 min, reca-
pitulation of data for 10 ng/mL EGF (ligand-only and pulse-
chase) was also generally good. The largest discrepancies
between model and experiment were observed for ligand-
only and pulse-chase kinetics for 1 ng/mL EGF, with the
model underestimating the former and overestimating the
latter. Thus, the model could not completely reconcile
the best-fit PTP kinetics with the modest induction of
EGFR phosphorylation for 1 ng/mL EGF.
Using parameters from fitting parental data only, the
model predicted that EGFR dephosphorylation would occur
within ~2 min in pulse-chase experiments in HeLa.DynK44A
cells, which is slower than the rate observed experimentally
(Fig. 3D). To refine our parameters, we refit themodel to data
including the HeLa.DynK44A pulse-chase data. Doing this,
kdp,s increased to a value slightly larger than kdp,i (Table 1)
and model agreement with HeLa.DynK44A pulse-chase data
improved (Fig. 3 D, solid black line) without altering
recapitulation of data from parental HeLas (Fig. 3,A–C, solid
lines). All remaining calculations use the refined model
parameters (Table 1).
Variations in the fit results among replicate fits led to
negligible variation in model output. Thus, we reportedBiophysical Journal 102(9) 2012–2021parameters for the lowest error among fits for given
conditions.Contributions of specific data and topological
features to fitting results
We further explored the fit results by examining variation in
the total model error and errors for individual experimental
conditions for variations in kdp,s and kdp,i. The other two fitted
parameters were left as listed in Table 1 because the model
was relatively insensitive to changes in these (see Fig. S3).
As expected, added consideration of the HeLa.DynK44A
pulse-chase data tightened the domain in kdp,s/kdp,i param-
eter space in which the total error was minimized (Fig. 4,
A and B). Agreement with data for response to EGF alone
was best for a kdp,i which was lower than that found by
regression against the complete data set (Fig. 4 C), whereas
agreement with pulse-chase data was best for a kdp,i which
was larger than that found by regression against all data
EGFR Regulation by Phosphatases 2017(Fig. 4 D). Not surprisingly, optimal model agreement with
HeLa.DynK44A cell pulse-chase data alone required a kdp,s
larger than that found for regression against all data
(Fig. 4 E). Interestingly, the HeLa.DynK44A cell pulse-chase
data also constrained kdp,i tightly, because these data include
an initial 8 min response to EGF alone. Optimal model
agreement with data from pervanadate (Fig. 4 F) was
achieved for kdp,s ~10
0 min1 and higher, resulting from a
need to explain increased receptor phosphorylation when
receptors were mainly at the cell surface. Interestingly, all
data considered tended to push kdp,s to nonnegligible values.
It may seem somewhat surprising, for example, that con-
sideration of the EGF data alone should require a substantial
kdp,s. Because our model framework considers phosphory-
lation in the absence of EGF, however, even explanation
of data for response to EGF alone requires PTP activity at
the plasma membrane.
The impact of different data used for regression was also
assessed by refitting parameters excluding various data (see
Table S2) or considering the various data individually (see
Table S3). Excluding each type of data (e.g., EGF treat-
ments only) individually revealed that no single treatment
condition was required for the conclusion that dephosphor-
ylation is rapid at the cell surface because each fit resulted in
a kdp,s of ~10
0 min1 (see Table S2). Fitting to data for each
treatment condition individually also resulted in kdp,s values
of at least ~100 min1 for all cases (see Table S3). The value
of kdp,i varied significantly among these fits, indicating that
consideration of multiple types of data is required to tightly
constrain this parameter.
To probe the impact of the phosphorylation-dependent
endocytosis model, we substituted the more common
modeling assumption that ligand-occupancy governs endo-
cytosis. These fits also resulted in a substantial value of kdp,s,
which was greater than kdp,i in some cases (see Table S4).
Only when we eliminated receptor phosphorylation in the
absence of ligand and fit the model to data for response to
ligand alone was kdp,i significantly larger than kdp,s (see
Table S5). To confirm that the ligand-independent phosphor-
ylation topology was not the only factor resulting in a kdp,sR
kdp,i, we refit the parameters with added consideration of
pulse-chase data, which resulted in a fitted kdp,s > kdp,i.
(see Table S5).Sensitivity analysis
To identify parameters that exert control over key model
behaviors, we performed a sensitivity analysis for the simu-
lation of a pulse-chase experiment and the calculation of ke,e
for 10 ng/mL EGF (see Fig. S3). Both analyses identified
parameters for EGF binding (kE,fs and kE,rs), EGFR dimeriza-
tion at the cell surface (kd,fs), phosphorylation in EGF-bound
dimers (kcatE), and kdp,s as important model parameters,
consistent with the key roles played by EGFR phosphoryla-
tion (which is promoted by ligand binding and dimerization)and dephosphorylation at the membrane. Interestingly,
the sensitivity of computing ke,e to changes in kdp,s (see
Fig. S3 A) is consistent with the recently reported role of
the receptor-like PTP DEP-1 in EGFR internalization and
degradation in HeLa cells (7). Pulse-chase dynamics were
also moderately sensitive to kdp,i (see Fig. S3 B). Sensitivity
to kdp,s and kdp,i suggests that substantial dephosphorylation
occurs before and after endocytosis for these conditions.Predicted effects of PTP activity on ligand-
mediated EGFR endocytosis
A key model assumption is that only phosphorylated
receptor species are endocytosed. Because the fit suggested
significant EGFR dephosphorylation at the membrane, and
because ke,e is somewhat sensitive to changes in kdp,s (see
Fig. S3 A), we used the model to predict the effect of PTP
activity on the rate of EGFR endocytosis. For a range of
base kdp,s values, SE and ke,mwere first computed. The values
of kdp,s and kdp,i were then set to 0 min
1, and ke,ewas calcu-
lated as previously described (34). For all nominal kdp,s
values, ke,e increased when PTP activity was eliminated
(Fig. 5 A, fold change in ke,e). The predicted effect on ke,e
increased as the base value of kdp,s increased because larger
ke,m values are required to maintain a constant base value of
ke,e as the base kdp,s increases (Fig. 5 A, ke,m). For the param-
eters in Table 1, the model predicted a modest increase in
ke,e from the base value of 0.13 to 0.15 min
1 when PTP
activity was eliminated.Effects of PTP activity on EGFR inhibition
We also used the model to predict the effect of eliminating
PTP activity on the inhibition of EGFR phosphorylation by
gefitinib. For each scenario, ke,m was consistent with a ke,e¼
0.13 min1, and the effects of 103–102 mM gefitinib on
EGFR phosphorylation response to 10 ng/mL EGF were
predicted (Fig. 5 B). The inhibition curves predicted for
elimination of internal or surface PTP activity were similar,
with IC50 shifts from ~0.1 mM for the base case to ~0.3 mM
for PTP elimination. The effect was slightly larger for
surface-compartmentalized PTPs at higher gefitinib con-
centrations because EGFR internalization is impeded by
gefitinib, resulting in surface-compartmentalized PTPs ex-
erting greater influence. Elimination of all PTP activity
had a much larger predicted effect (IC50 shift from ~0.1 to
~2 mM) due to a coupling of kinetic phenomena beyond
the scope of this discussion. Overall, these results suggest
that EGFR inhibitor efficacy depends heavily upon the
magnitude and localization of PTP activity.EGFR phosphate cycling
Our results suggest that EGFR tyrosines cycle between
phosphorylated and unphosphorylated states more rapidlyBiophysical Journal 102(9) 2012–2021
FIGURE 6 Analysis of EGFR tyrosine phosphate cycling. (A) Estimates
of tyrosine phosphate cycling rates were made for EGF-occupied
and -unoccupied EGFR at the cell surface (SþE and SE, respectively)
and for EGF-occupied and -unoccupied EGFR in the cell interior
(IþE and IE, respectively). (B) EGFR phosphate flux was calculated by
computing the total phosphorylation rate as a function of time for treatment
with 0–100 ng/mL EGF. (C and D) Steady-state phosphorylated (% max
pEGFR, solid lines) and unphosphorylated (% max upEGFR, dashed lines)
EGFR levels, reported as percentages of the maximum steady value for
each curve, were calculated for ke,m ¼ 0 min1, a range of EGFR levels,
1 ng/mL EGF, and (C) kdp,s ¼ 104, 102, or 100 min1 and (D) kd,fs ¼
105, 104, or 103 min1.
FIGURE 5 Predicted effect of dephosphorylation kinetics on EGF-
mediated EGFR endocytosis and EGFR phosphorylation inhibition. (A)
The predicted effect of eliminating all PTP activity on ke,e for 10 ng/mL
EGF was calculated as a function of kdp,s. Data are presented as a fold-
change relative to the value of ke,e before elimination of PTP activity (black
line). Corresponding ke,m values are also shown (gray line). (B) The effect of
5-min pretreatment with 103–102 mM gefitinib on EGFR phosphorylation
response to a 20-min treatment with 10 ng/mLEGFwas calculated. For each
curve, model output was normalized to the pEGFR value predicted without
inhibitor. Predictions were made for no change to PTP activity (base) and for
elimination of PTP activity (at t¼ 0) at the plasma membrane (kdp,s¼ 0), in
the cell interior (kdp,i¼ 0), and in both compartments (kdp,s¼ kdp,i¼ 0). For
each curve, ke,m was chosen to be consistent with a ke,e ¼ 0.13 min1.
2018 Monast et al.than is generally appreciated. This is analogous to the well-
known example of phosphofructokinase and fructose-1,6-
bisphosphatase and the so-called futile cycling process
they mediate between fructose-6-phosphate and fructose-
1,6-bisphosphate (39). The term ‘‘futile cycling’’ refers to
a switching between states on a timescale smaller than other
important process timescales. Although this cycling is more
rapid than necessary for signal output magnitudes achiev-
able with slower cycling, rapid cycling may result in key
system robustness qualities (9–12). For EGFR, this cycling
may also regulate receptor endocytosis and pharmacological
inhibition, as we discuss.
Using the relevant phosphorylation and dephosphoryla-
tion rate constants, rates of EGFR phosphate cycling were
estimated for ligand-bound and -free EGFR at the mem-
brane and in the cell interior (Fig. 6 A). The estimated rateBiophysical Journal 102(9) 2012–2021was highest (~1.5 cycles/min) for ligand-bound receptors
at the cell surface because the kinetics of phosphorylation
and dephosphorylation are most rapid for that scenario.
We also estimated dynamic rates of ATP consumption by
EGFR for four EGF concentrations (Fig. 6 B) and compared
these to an estimate of ATP consumption for cultured cells
of 4  108 ATP$min1$cell1 (40). We thus estimated
that EGFR phosphate cycling for a single tyrosine repre-
sents %0.008% of cellular ATP consumption in a cell
with 5  104 EGFR.
We also explored analogies of our results with those of
the well-known study of phosphate cycling by Goldbeter
and Koshland (11), who demonstrated that sensitivity to
changes in reaction velocities depends upon Michaelis-
Menten-like constants for phosphorylation and dephosphor-
ylation. Whereas Goldbeter and Koshland analyzed a model
where the enzyme and substrate were distinct species,
EGFR is both an enzyme and a substrate, which introduces
an important topological difference. In addition, PTP con-
centration is not specified in our model, because dephos-
phorylation is treated as a zeroth order process. To explore
EGFR Regulation by Phosphatases 2019model similarities, we varied the analog of their velocity V1
in our model by changing EGFR expression and the analog
of their dephosphorylation rate constant k2 by changing our
kdp,s and computed the EGFR phosphorylation response to
1 ng/mL EGF as a percent of the maximum phosphorylated
EGFR level achieved for a given parameter set (Fig. 6, C
and D). Consistent with the general behavior described by
Goldbeter and Koshland, lowering kdp,s increased the sensi-
tivity of steady EGFR phosphorylation levels to changes in
EGFR level (Fig. 6 C). Lowering the rate constant for EGFR
dimerization, an analog for lowering the a1 parameter of
Goldbeter and Koshland (11), decreased the sensitivity of
steady EGFR phosphorylation levels to changes in EGFR
levels (Fig. 6 D). EGFR phosphorylation was not sensitive
to changes in the EGFR phosphorylation rate constant
because the phosphorylation step is not rate-limiting for
the model as described by the parameters in Table 1 (see
Fig. S4).DISCUSSION
Our results suggest that the EGFR phosphorylation
dynamics we observed experimentally are consistent with
timescales for EGFR dephosphorylation at the plasma
membrane and in the cell interior that are smaller than the
timescale for EGF-mediated EGFR endocytosis. This result
stands in stark contrast to the classical view of EGFR phos-
phorylation dynamics wherein receptor phosphorylation
occurs at the plasma membrane and dephosphorylation
occurs after endocytosis. Of course, the classical view is
generally consistent with the apparent timescale for receptor
dephosphorylation suggested by EGFR phosphorylation in
response to EGFR ligands alone. Given that most studies
of EGFR phosphorylation dynamics probe response to
ligands alone, it is perhaps not surprising that this classical
view of receptor phosphorylation is so pervasive.
Although certain experiments in our study plainly re-
vealed the importance of EGFR dephosphorylation at the
plasma membrane (e.g., experiments with HeLa.DynK44A
cells), the incorporation of certain novel model topological
features revealed the same thing when considering other
data where the need for PTP activity was less obvious. For
example, substantial PTP activity in the membrane com-
partment is required to maintain low basal levels of EGFR
phosphorylation in a model that allows receptor phosphory-
lation in the absence of ligand to proceed as rapidly as we
observed with pervanadate treatment.
The possibility that EGFR dephosphorylation may occur
at different rates at the plasma membrane and in the cell
interior was explored in a previous computational study
(6), but the authors of that study concluded that ErbB re-
ceptor dephosphorylation occurred primarily in the cell
interior for two different ErbB ligands. That study sought
to qualitatively reconcile model predictions with receptor
phosphorylation response to ligands only. There are alsoa number of topological differences between that model
and ours, among them that the previous model did not con-
sider receptor phosphorylation in the absence of ligand. All
of these differences together likely explain the very different
conclusion reached in that study versus the conclusions of
our study.
Our implementation of a phosphorylation-dependent
internalization model (which has been used in at least
one previous study (21)), instead of a ligand occupancy
model as in other studies (6,19,20), is well supported by
experimental data, as reviewed by Sorkin and Goh (1).
For example, mutation of key EGFR tyrosines reduced
EGF-mediated EGFR internalization rates in mouse fibro-
blasts, suggesting that tyrosine phosphorylation is indeed
required for efficient ligand-mediated EGFR endocytosis
(1). It should also be emphasized, however, that our
particular implementation of phosphorylation-dependent
receptor internalization is novel, to the best of our
knowledge. Specifically, our iterative calculation of ke,m
values that lead to optimum model matching of experi-
mentally reported ke,e values is an important and, we
believe, unique way in which our model recapitulates
experimental data.
Because our studies concluded that substantial EGFR
dephosphorylation occurs at the plasma membrane, and
because we have implemented a phosphorylation-dependent
model for EGFR endocytosis, it was not surprising that the
model predicted that PTP activity at the plasma membrane
may impede EGFR endocytosis (Fig. 5 A). Interestingly,
this model-predicted effect is qualitatively consistent with
the apparent effect of knockdown of the receptor-like
PTP DEP-1 on EGFR internalization observed recently in
HeLa cells (7). We applied our model to estimate that Tarcic
et al. (7) observed a decrease in surface-localized EGFR
in response to EGF consistent with ke,e ¼ 0.2 min1 in their
flow cytometry data for control cells and a threefold increase
in ke,e with DEP-1 knockdown. Assuming DEP-1 accounts
for all PTP activity at the plasma membrane, our model
predicts a threefold increase in ke,e with a kdp,s ~3 
101 min1 (Fig. 5 A), which is significantly larger than the
best fit kdp,s (Table 1). Of course, our model results represent
the predicted effect of instantaneous inhibition of PTP
activity. It is possible that knockdown of DEP-1 resulted
in an adaptive response that amplified the effect of DEP-1
knockdown in the experiments of Tarcic et al. (7). In addi-
tion, it is possible that the tendency of at least some
EGFR antibodies to not efficiently recognize pEGFR (noted
in the Supporting Material) resulted in an effect on EGFR
levels that was more apparent than real in the data of Tarcic
et al. (7).
Our model results regarding PTP activity at the plasma
membranewere directly tested through comparison of model
predictions with pulse-chase experiments in HeLa.DynK44A
cells. Although the model parameters fitted through consid-
eration of parental HeLa cell data only did a reasonable jobBiophysical Journal 102(9) 2012–2021
2020 Monast et al.of predicting the rate at which plasma-membrane-seques-
tered receptors were dephosphorylated, consideration of
the HeLa.DynK44A cell data in a refitting of the model
aided in refining our parameter estimates. In the future,
it will be interesting and important to also directly test
other model predictions (e.g., the effects of PTP inhibition
on EGFR pharmacological inhibition) and to use such
results to refine the model in a similar way. Another partic-
ularly important aspect of the biochemistry we investigated
that would be important to understand more deeply is the
extent to which PTP activity, with respect to EGFR, is
time-dependent for the various cell treatment conditions
utilized in our study. Surprisingly, very little has been re-
ported on this subject. As far as we are aware, only
changes in the activity of the cytosolic PTP SHP2 in
response to ligands including EGF have been studied in
any detail (41).
Although our study focuses on receptor-level regulation,
phosphatases have been considered in some models of
signaling processes distal to receptors. For example, the
models developed by Heinrich et al. (12) for generalized
linear signaling cascades demonstrated the role of phospha-
tases in setting the amplitude, duration, and amplification
of signaling responses to upstream changes in receptor
activation. Our model similarly points to a key role for
PTPs in determining EGFR phosphorylation amplitude
and duration. Importantly, this regulation is revealed by
our model to occur on a timescale that is smaller than
that for other important process timescales, including the
typical timescale for complete activation of MAP kinase
cascades and receptor trafficking. Incorporation of these
receptor-level considerations revealed by our study in
models including downstream cascades may help to more
fully recapitulate dynamic signaling data that spans the
space from the receptor to key downstream-signaling
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